source
- Turn Therapeutics' eczema drug shows rapid response in mid-stage dataCalifornia biotech Turn Therapeutics shared Phase 2 data for its topical atopic dermatitis treatment that show patients experienced symptom improvement faster than usual. In an interim analysis of…Endpoints · 1mo ago↗ source
- Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assetsServier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…Endpoints · 1mo ago↗ source
- STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drugThe French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.